Vandetanib 100mg Tablets

Vandetanib 100mg Tablets represent a specialized targeted therapy used primarily in the management of rare thyroid malignancies. Pharmacologically, vandetanib is a multi-kinase inhibitor that simultaneously targets several key receptors involved in tumor growth and angiogenesis (blood vessel formation). Its primary targets include the Vascular Endothelial Growth Factor Receptor (VEGFR), the Epidermal Growth Factor Receptor (EGFR), and the RET (Rearranged during Transfection) tyrosine kinase.

In Medullary Thyroid Cancer (MTC), mutations in the RET proto-oncogene are a frequent driver of disease. By inhibiting the RET kinase, Vandetanib 100mg Tablets directly block the signaling pathway that instructs the cancer cells to divide. Concurrently, by inhibiting VEGFR, the medication cuts off the blood supply to the tumor (anti-angiogenesis), starving it of the oxygen and nutrients needed for growth. This dual mechanism of attacking the tumor cells directly while also disrupting their microenvironment makes it a potent option for controlling aggressive disease.

Indications / Uses of Vandetanib 100mg Tablets

Vandetanib 100mg Tablets are indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable, locally advanced, or metastatic disease. Because of the associated risks, it is generally reserved for patients whose disease is causing significant symptoms or is growing clinically. Common uses include:

• Symptomatic MTC: Prescribed for patients experiencing burden from the tumor burden, such as pain or compression of neck structures, where surgical resection is not possible.
• Progressive Disease: Indicated when the cancer is actively growing or spreading, as demonstrated by imaging, to slow or arrest tumor progression.
• RET-Mutated or Sporadic MTC: While often effective in tumors with RET mutations, it is also indicated for sporadic cases of MTC where the driver mutation may not be known, due to its multi-kinase inhibitory effects.
• Dose Reduction: The 100mg tablet is essential for dose modifications. The starting dose is typically 300mg, but patients frequently require reduction to 200mg or 100mg to manage toxicities like diarrhea or QT prolongation.

Key Features

• Multi-Target Inhibition: By blocking EGFR, VEGFR, and RET pathways, it attacks the tumor on multiple fronts—proliferation, survival, and blood supply.
• Long Half-Life: Vandetanib has an exceptionally long half-life of approximately 19 days. This means steady-state levels are achieved slowly (over months), and the drug remains in the system for weeks after stopping treatment.
• Oral Administration: The tablet formulation allows for once-daily oral dosing, which can be taken with or without food.
• PFS Improvement: Clinical trials (ZETA trial) demonstrated a significant improvement in progression-free survival (PFS) compared to placebo in patients with locally advanced or metastatic MTC.

Storage for Vandetanib 100mg Tablets

To ensure the stability of Vandetanib 100mg Tablets, proper storage is required. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the tablets in their original container to protect them from light and moisture. Do not store the medication in humid environments like bathrooms. Ensure the container is tightly closed and kept out of the reach and sight of children and pets.

Important Note on Vandetanib 100mg Tablets

Treatment with Vandetanib 100mg Tablets carries a Boxed Warning for QT Prolongation, Torsades de Pointes, and Sudden Death. The drug can significantly disrupt the heart’s electrical rhythm. Consequently, it is available only through a restricted distribution program called the Vandetanib REMS Program.

Electrocardiograms (ECGs) and serum levels of potassium, calcium, and magnesium must be obtained at baseline, at 2-4 weeks and 8-12 weeks after starting treatment, and every 3 months thereafter. Electrolyte abnormalities must be corrected before and during treatment.

Photosensitivity is a common side effect; patients can develop severe sunburns with minimal sun exposure. Patients must use protective clothing and high-SPF sunscreen during treatment and for 4 months after discontinuation.

Diarrhea is frequently reported and can be severe; prompt management with electrolytes and anti-diarrheals is often necessary. Due to the long half-life, adverse reactions may persist for weeks after the drug is stopped. It is not recommended for use in patients with moderate to severe hepatic impairment or renal impairment.